| 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable … GY Ku, M Di Bartolomeo, E Smyth, I Chau, H Park, S Siena, S Lonardi, ... Annals of Oncology 33, S1100, 2022 | 33 | 2022 |
| 121MO ctDNA and prognosis in resected esophageal adenocarcinoma (EAC) E Ococks, AM Frankell, NM Soler, A Northrop, H Coles, N Grehan, ... Annals of Oncology 31, S1290, 2020 | | 2020 |
| 1253P Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: Phase IIa … FS Turkes, R Crux, A Tran, E Cartwright, I Rana, E Johnston, A Dunlop, ... Annals of Oncology 33, S1120-S1121, 2022 | | 2022 |
| 1412P Palliative stents in a large cohort of advanced gastroesophageal cancers (GOC): Factors associated with long term survival C Hannon, B Paula, M Goksu, G Corbett, N Carroll, C Sousa, E Smyth Annals of Oncology 32, S1061, 2021 | 1 | 2021 |
| 145O Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results EC Smyth, N Turner, A Pearson, C Peckitt, I Chau, D Watkins, E Kilgour, ... Annals of Oncology 26, ix42, 2015 | 2* | 2015 |
| 1491P bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients E Ococks, A Ng, G Devonshire, S Dashner, WC Chan, S Sharma, HT Wu, ... Annals of Oncology 31, S926, 2020 | 1 | 2020 |
| 1572P Impact of HER2 and PD-L1 co-expression in Claudin18. 2 positive resectable gastroesophageal cancers A Cammarota, G Devonshire, A Miremadi, A Ustaoglu, B Filippi, ... Annals of Oncology 34, S877-S878, 2023 | | 2023 |
| 161P Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer T Fujii, G Prager, S Boeck, D Santini, DP Modest, F Rivera, JM Phelip, ... Annals of Oncology 34, S1538, 2023 | | 2023 |
| 1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC … C Linossi, IG Funingana, M Petruzzelli, BHR de Paula, M O'Donovan, ... Annals of Oncology 31, S1096, 2020 | | 2020 |
| 195P Carboplatin for operable oesophageal and gastric adenocarcinoma (OGA): Royal Marsden (RMH) experience 2001-2010 E Fontana, EC Smyth, D Cunningham, W Allum, J Thompson, T Waddell, ... Annals of Oncology 26, ix42, 2015 | | 2015 |
| 2018 POSTER Can differences in cellular antioxidant enzyme status predispose to breast cancer in women without a recognised increased risk? S Chaturvedi, KWJ Wahle, SD Heys, G Bermano, E Smyth, S McIntosh, ... EJC Supplements 4 (5), 189, 2007 | | 2007 |
| 2201 Peri-operative chemotherapy±bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948) D Cunningham, E Smyth, S Stenning, L Stevenson, C Robb, W Allum, ... European Journal of Cancer 3 (51), S400, 2015 | 43 | 2015 |
| 27 years of stomach cancer: painting a global picture A Petrillo, EC Smyth The Lancet Gastroenterology & Hepatology 5 (1), 5-6, 2020 | 11 | 2020 |
| 370P Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients E Ococks, A Ng, G Devonshire, S Dashner, WC Chan, S Sharma, HT Wu, ... Annals of Oncology 31, S1317-S1318, 2020 | | 2020 |
| 4.8. 2. b GE Junction Cancer. N Beri, EC Smyth ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology …, 2023 | | 2023 |
| 422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data … E Fontana, C Zichi, EC Smyth, M Mauer, C Rödel, E Fokas, RD Hofheinz, ... Annals of Oncology 31, S420-S421, 2020 | | 2020 |
| 443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and … E Cartwright, F Turkes, C Saffery, A Tran, G Smith, SE Moreno, S Hatt, ... Annals of Oncology 32, S555-S556, 2021 | 5 | 2021 |
| 465P Timing of first-line palliative systemic therapy in metastatic Esophagogastric cancer (mEGC): A European Delphi study D Kamp, AM May, A Adenis, AC Marques, S Derks, F Defelice, NF Dovnik, ... Annals of Oncology 35, S186-S187, 2024 | | 2024 |
| 495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18. 2 (CLDN18. 2)-targeted antibody-drug conjugate, in second-or later-line (2L+) advanced gastric … K Shitara, YY Janjigian, E Elimova, J Zhang, MH Chen, E Smyth, J Lee, ... Annals of Oncology 35, S196-S197, 2024 | | 2024 |
| 499TiP A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN … E Smyth, D Griffiths, K Cozens, C Hurt, R Waugh, R Turkington, K Foley, ... Annals of Oncology 35, S199, 2024 | | 2024 |
